share_log

Altimmune | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Altimmune | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Altimmune | S-8：員工福利計劃證券登記
SEC announcement ·  03/27 16:15
Moomoo AI 已提取核心訊息
Altimmune, Inc., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on March 27, 2024. This filing pertains to the registration of an additional 3,055,006 shares of common stock under the company's 2017 Omnibus Incentive Plan. The plan allows for an automatic annual increase in the number of shares available for issuance, which is determined on January 1 of each year, based on a set formula. The newly registered shares are of the same class as those previously registered under the 2017 Plan. Altimmune's CEO, Dr. Vipin K. Garg, along with other executives and directors, have signed the Registration Statement, indicating their compliance with the requirements for filing on Form S-8.
Altimmune, Inc., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on March 27, 2024. This filing pertains to the registration of an additional 3,055,006 shares of common stock under the company's 2017 Omnibus Incentive Plan. The plan allows for an automatic annual increase in the number of shares available for issuance, which is determined on January 1 of each year, based on a set formula. The newly registered shares are of the same class as those previously registered under the 2017 Plan. Altimmune's CEO, Dr. Vipin K. Garg, along with other executives and directors, have signed the Registration Statement, indicating their compliance with the requirements for filing on Form S-8.
生物製藥公司Altimmune, Inc. 已於2024年3月27日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件涉及根據公司2017年綜合激勵計劃另外註冊3,055,006股普通股。該計劃允許每年自動增加可供發行的股票數量，該數量根據設定的公式在每年1月1日確定。新註冊的股票與先前根據2017年計劃註冊的股票屬於同一類別。Altimmune的首席執行官Vipin K. Garg博士以及其他高管和董事簽署了註冊聲明，表示他們遵守了提交S-8表格的要求。
生物製藥公司Altimmune, Inc. 已於2024年3月27日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件涉及根據公司2017年綜合激勵計劃另外註冊3,055,006股普通股。該計劃允許每年自動增加可供發行的股票數量，該數量根據設定的公式在每年1月1日確定。新註冊的股票與先前根據2017年計劃註冊的股票屬於同一類別。Altimmune的首席執行官Vipin K. Garg博士以及其他高管和董事簽署了註冊聲明，表示他們遵守了提交S-8表格的要求。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息